Berberis aristata combined with Silybum marianum on lipid profile in patients not tolerating statins at high doses. Issue 1 (March 2015)

• Record Type: Journal Article
• Authors: Derosa, Giuseppe; Romano, Davide; D'Angelo, Angela; Maffioli, Pamela
• Is Part Of: Atherosclerosis. Volume 239:Issue 1(2015)
• Page Start: 87
• Page End: 92
• Publication Date: 2015-03
• Subjects: Arteriosclerosis -- Periodicals; Electronic journals; 616.136
• DOI: 10.1016/j.atherosclerosis.2014.12.043
• Languages: English
• ISSNs: 0021-9150

Abstract

<abstract xml:lang="en" abstract-type="author" id="abs0010"> <title id="sectitle0010">Abstract</title> <sec> <title id="sectitle0015">Aim</title> <p id="abspara0010">To evaluate the effects of <italic>Berberis aristata</italic> combined with <italic>Silybum marianum</italic> in dyslipidemic patients intolerant to statins at high doses.</p> </sec> <sec> <title id="sectitle0020">Methods</title> <p id="abspara0015">137 euglycemic, dyslipidemic subjects, with previous adverse events to statins at high doses, were enrolled. Statins were stopped for 1 month (run-in), then they were re-introduced at the half of the previously taken dose. At randomization, patients tolerating the half dose of statin, were assigned to add placebo or <italic>B. aristata</italic>/<italic>S. marianum</italic> 588/105 mg, 1 tablet during the lunch and 1 tablet during the dinner, for six months. We evaluated lipid profile and safety parameters variation at randomization, and after 3, and 6 months.</p> </sec> <sec> <title id="sectitle0025">Results</title> <p id="abspara0020"> <italic>B. aristata</italic>/<italic>S. marianum</italic> reduced fasting plasma glucose (−9 mg/dl), insulin (−0.7 μU/ml), and HOMA-index (−0.35) levels compared to baseline and also to placebo. Lipid profile did not significantly change after 6 months since the reduction of statin dosage and the introduction of <italic>B. aristata</italic>/<italic>S. marianum</italic>, while it worsened in the placebo group both compared to placebo and with active treatment (+23.4 mg/dl for total cholesterol, +19.6 mg/dl for LDL-cholesterol, +23.1 mg/dl for triglycerides with placebo compared to <italic>B. aristata</italic>/<italic>S. marianum</italic>). We did not record any variations of safety parameters in nether of groups.</p> </sec> <sec> <title id="sectitle0030">Conclusions</title> <p id="abspara0025"> <italic>B. aristata</italic>/<italic>S. marianum</italic> can be considered as addition to statins in patients not tolerating high dose of these drugs.</p> </sec> </abstract>